scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/13/24
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024GlobeNewsWire • 03/06/24
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® RevenueGlobeNewsWire • 01/04/24
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/08/23
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023GlobeNewsWire • 11/01/23
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/05/23
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth InitiativesGlobeNewsWire • 09/19/23
scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/10/23
scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/23
scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023GlobeNewsWire • 08/03/23
scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication ExpansionGlobeNewsWire • 08/01/23
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 07/18/23
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® IndexesGlobeNewsWire • 06/23/23